Affinity Asset Advisors LLC Sells 1,000,000 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Affinity Asset Advisors LLC cut its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 41.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,400,000 shares of the company’s stock after selling 1,000,000 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 4.1% of Affinity Asset Advisors LLC’s holdings, making the stock its 5th largest holding. Affinity Asset Advisors LLC owned about 0.12% of Teva Pharmaceutical Industries worth $30,856,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Stifel Financial Corp raised its stake in Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its stake in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock worth $10,983,000 after purchasing an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth $4,966,000. Asset Management One Co. Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 14.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after purchasing an additional 58,413 shares during the period. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $3,340,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.9 %

TEVA stock opened at $13.58 on Tuesday. The firm’s 50-day moving average is $15.71 and its two-hundred day moving average is $17.79. The company has a market capitalization of $15.40 billion, a price-to-earnings ratio of -9.37, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TEVA. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. StockNews.com downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Monday. Bank of America lowered their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. Finally, UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.